TY - JOUR
T1 - Immunotherapy of oneiric stupor in Morvan syndrome
T2 - Efficacy documented by actigraphy
AU - Baiardi, Simone
AU - Provini, Federica
AU - Avoni, Patrizia
AU - Pasquinelli, Marco
AU - Liguori, Rocco
PY - 2015/6/16
Y1 - 2015/6/16
N2 - Morvan syndrome (MoS) is a rare acquired channelopathy associated with autoantibodies against potassium channel complex and clinically characterized by the heterogeneous combination of neuromyotonia, dysautonomia, and encephalopathy.1 Peculiar CNS symptoms are organic insomnia, which ranges from mild to malignant forms characterized by complete loss of sleep, and persistent motor/autonomic hyperactivation (agrypnia excitata2). We describe a patient with MoS who developed progressive agrypnia excitata, in which IV immunoglobulin (IVIg) treatment induced a progressive recovery of the physiologic sleep-wake cycle, documented by videopolysomnography (VPSG) and actigraphic monitoring.
AB - Morvan syndrome (MoS) is a rare acquired channelopathy associated with autoantibodies against potassium channel complex and clinically characterized by the heterogeneous combination of neuromyotonia, dysautonomia, and encephalopathy.1 Peculiar CNS symptoms are organic insomnia, which ranges from mild to malignant forms characterized by complete loss of sleep, and persistent motor/autonomic hyperactivation (agrypnia excitata2). We describe a patient with MoS who developed progressive agrypnia excitata, in which IV immunoglobulin (IVIg) treatment induced a progressive recovery of the physiologic sleep-wake cycle, documented by videopolysomnography (VPSG) and actigraphic monitoring.
UR - http://www.scopus.com/inward/record.url?scp=84931032966&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931032966&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000001694
DO - 10.1212/WNL.0000000000001694
M3 - Article
C2 - 25979695
AN - SCOPUS:84931032966
VL - 84
SP - 2457
EP - 2459
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 24
ER -